




[Fig.1]




[Fig.2]




[Fig.3]




[Fig.4]




[Fig.5]




[Fig.6]




[Fig.7]



[Fig.8]




[Fig.9]




Sample	$t_{50\%}$
DDV(200) ₁₀	57.4 h
DDV(500) ₁₀	37.5 h
DDV(1000) ₁₀	30.0 h

[Fig.10]




Samples	$t_{50\%}$
MSN(200) ₂	17.9 h
DDV(200) ₁₀	57.4 h
DDV(200) ₁₇	53.6 h

[Fig.11]



[Fig.12]



The graph illustrates the cumulative drug release of Doxorubicin over a 72-hour period. The y-axis represents the cumulative drug release in percentage, ranging from 0 to 100. The x-axis represents time in hours, ranging from 0 to 70. The release curve is characterized by a steep initial phase followed by a more gradual, sustained release. A dashed line indicates that approximately 50% of the drug is released at $t_{50\%} \approx 6.5$ hours.

Time (h)	Cumulative drug release (%)
0	0
1	25
2	35
3	40
6.5	48
10	52
12	56
18	60
24	63
48	68
72	74

Doxorubicin

COc1ccc2c(c1)C(=O)c3c(O)c(O)c(O)c3C2[C@@H]4O[C@H](C[C@@H]5[C@H](O)[C@@H](CO)O[C@H]5N)[C@H](O)[C@H]4O


Irinotecan release profile in human plasma

The graph illustrates the cumulative drug release of Irinotecan in human plasma over a period of 120 hours. The y-axis represents the cumulative drug release as a percentage, ranging from 0 to 100. The x-axis represents time in hours, ranging from 0 to 120. The release profile shows a rapid initial release, reaching approximately 95% within 100 hours. A dashed line indicates that 50% of the drug is released at approximately 5.5 hours ($t_{50\%} \approx 5.5$ hrs). The chemical structure of Irinotecan is shown.


Irinotecan

CC1=C(C(=O)OCC2=CC=CC=C2C3=C1C(=O)N(C3)C4=CC=CC=C4C5=CC=C(C=C5)OC(=O)N6CCN(CC6)C7CCCCC7)C8=CC=CC=C8


[Fig.15]




[Fig.16]




[Fig.17]




[Fig.18]




[Fig.19]




[Fig.20]




[Fig.21]




[Fig.22]




[Fig.23]




[Fig.24]



[Fig.25]



[Fig.26]



[Fig.27]

